Formulations of an AXL/MER inhibitor

1. A pharmaceutical formulation in solid oral dosage form comprising:

(a) N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo [2,1-f][1,2,4]triazin-5 -yl)phenyl)-1-isopropyl-2, 4-dioxo-3 -(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5 -carboxamide (Compound I), or a pharmaceutically acceptable salt, solvate or hydrate thereof;

(b) an organic acid; and

(c) a surfactant.

2. The pharmaceutical formulation of claim 1 , wherein the organic acid is citric acid, ascorbic acid, fumaric acid, malic acid, sorbic acid, or tartaric acid.

3. The pharmaceutical formulation of claim 1 , wherein the organic acid is citric acid.

4. The pharmaceutical formulation of claim 1 , comprising about 1 wt % to about 50 wt % of organic acid.

5. The pharmaceutical formulation of claim 1 , comprising about 5 wt % to about 40 wt % of organic acid.

6. The pharmaceutical formulation of claim 1 , comprising about 5 wt % to about 30 wt % of organic acid.

7. The pharmaceutical formulation of claim 1 , comprising about 10 wt % to about 20 wt % of organic acid.

8. The pharmaceutical formulation of claim 1 , comprising about 10 wt % or about 20 wt % of organic acid.

9. The pharmaceutical formulation of claim 1 , comprising about 1 wt % to about 20 wt % of Compound I, or a pharmaceutically acceptable salt thereof, on a free base basis.

10. The pharmaceutical formulation of claim 1 , comprising about 2 wt % to about 15 wt % of Compound I, or a pharmaceutically acceptable salt thereof, on a free base basis.

11. The pharmaceutical formulation of claim 1 , comprising about 3 wt % or about 12 wt % of Compound I, or a pharmaceutically acceptable salt thereof, on a free base basis.

12. The pharmaceutical formulation of claim 1 , wherein the surfactant is a poloxamer.

13. The pharmaceutical formulation of claim 1 , wherein the surfactant is poloxamer 407 or poloxamer 188.

14. The pharmaceutical formulation of claim 1 , wherein the surfactant is poloxamer 407.

15. The pharmaceutical formulation of claim 1 , comprising about 1 wt % to about 20 wt % of surfactant.

16. The pharmaceutical formulation of claim 1 , comprising about 5 wt % to about 15 wt % of surfactant.

17. The pharmaceutical formulation of claim 1 , comprising about 5 wt % to about 10 wt % of surfactant.

18. The pharmaceutical formulation of claim 1 , comprising about 1 wt % to about 10 wt % of surfactant.

19. The pharmaceutical formulation of claim 1 , further comprising a diluent.

20. The pharmaceutical formulation of claim 19 , wherein the diluent is mannitol.

21. The pharmaceutical formulation of claim 19 , comprising about 40 wt % to about 90 wt % of diluent.

22. The pharmaceutical formulation of claim 19 , comprising about 50 wt % to about 80 wt % of diluent.

23. The pharmaceutical formulation of claim 19 , comprising about 50 wt % to about 75 wt % of diluent.

24. The pharmaceutical formulation of claim 1 , further comprising a disintegrant.

25. The pharmaceutical formulation of claim 24 , wherein the disintegrant is crospovidone.

26. The pharmaceutical formulation of claim 24 , comprising about 1 wt % to about 10 wt % of disintegrant.

27. The pharmaceutical formulation of claim 24 , comprising about 2 wt % to about 5 wt % of disintegrant.

28. The pharmaceutical formulation of claim 1 , further comprising a lubricant, glidant, or both.

29. The pharmaceutical formulation of claim 28 , wherein the lubricant is stearic acid.

30. The pharmaceutical formulation of claim 28 , comprising about 1 wt % to about 5 wt % of lubricant.

31. The pharmaceutical formulation of claim 28 , comprising about 2 wt % of lubricant.

32. The pharmaceutical formulation of claim 28 , wherein the glidant is colloidal silica.

33. The pharmaceutical formulation of claim 28 , comprising about 0.1 wt % to about 5 wt % of glidant.

34. The pharmaceutical formulation of claim 28 , comprising about 0.5 wt % or about 1 wt % of glidant.

35. A pharmaceutical formulation comprising:

(a) N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo [2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2, 4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I), or a pharmaceutically acceptable salt, solvate or hydrate thereof;

(b) citric acid; and

(c) a poloxamer.

36. The pharmaceutical formulation of claim 1 , wherein the salt is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2, 1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3, 4-tetrahydropyrimidine-5-carboxamide maleate (Compound I maleate).

37. The pharmaceutical formulation of claim 36 , comprising about 1 wt % to about 20 wt % of Compound I maleate.

38. The pharmaceutical formulation of claim 36 , comprising about 2 wt % to about 15 wt % of Compound I maleate.

39. The pharmaceutical formulation of claim 36 , comprising about 3 wt % or about 12 wt % of Compound I maleate.

40. A pharmaceutical formulation comprising:

(a) about 2 wt % to about 15 wt % of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, on a free base basis;

(b) about 5 wt % to about 30 wt % of citric acid; and

(c) about 5 wt % to about 15 wt % a poloxamer.

41. A pharmaceutical formulation comprising:

(a) about 2 wt % to about 15 wt % of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, on a free base basis;

(b) about 5 wt % to about 30 wt % of citric acid;

(c) about 5 wt % to about 15 wt % poloxamer 407;

(d) about 50 wt % to about 80 wt % mannitol;

(e) about 1 wt % to about 5 wt % stearic acid; and

(f) about 2 wt % to about 5 wt % crospovidone.

42. A pharmaceutical formulation comprising:

(a) about 2 wt % to about 15 wt % of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, on a free base basis;

(b) about 5 wt % to about 30 wt % of citric acid; and

(c) about 1 wt % to about 10 wt % a poloxamer.

43. A pharmaceutical formulation comprising:

(a) about 2 wt % to about 15 wt % of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, on a free base basis;

(b) about 5 wt % to about 30 wt % of citric acid;

(c) about 1 wt % to about 10 wt % poloxamer 407;

(d) about 50 wt % to about 80 wt % mannitol;

(e) about 1 wt % to about 5 wt % stearic acid; and

(f) about 2 wt % to about 5 wt % crospovidone.

44. The pharmaceutical formulation of claim 40 , wherein the salt is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (Compound I maleate).

45. The pharmaceutical formulation of claim 1 , wherein Compound I, or a pharmaceutically acceptable salt, hydrate or solvate thereof, is in crystalline form.

46. The pharmaceutical formulation of claim 1 , wherein the dosage form is a tablet or capsule.

47. The pharmaceutical formulation of claim 1 , wherein the dosage form is a capsule.

48. A method for inhibiting AXL and MER kinase, said method comprising contacting the AXL and MER kinase with a pharmaceutical formulation of claim 1 .

49. A method for treating a cancer in a patient, said method comprising: administering to the patient a therapeutically effective amount of a pharmaceutical formulation of claim 1 , wherein the cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, rhabdosarcoma, colon cancer, renal cell carcinoma, and rhabdomyosarcoma.

50. The method of claim 49 , wherein the cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

51. The method of claim 49 , wherein the cancer is lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, renal cell carcinoma, multiple myeloma, gastric cancer, or rhabdomyosarcoma.

52. A method for preparing a pharmaceutical formulation suitable for oral administration comprising blending N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f] [1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof; an organic acid; and a surfactant to form the pharmaceutical formulation suitable for oral administration.

53. The method of claim 52 , further comprising compressing the pharmaceutical formulation to afford a capsule.

54. The pharmaceutical formulation of claim 1 , prepared by the method of claim 52 .

55. The pharmaceutical formulation of claim 1 , wherein the organic acid is C 1-6 alkyl, C 2-6 alkenyl, or 5-6 membered heterocycloalkyl, each substituted with one or more acidic groups, wherein the 5-6 membered heterocycloalkyl is optionally substituted with a C 1-6 alkyl group that is optionally substituted with one or more acidic groups.

56. The pharmaceutical formulation of claim 1 , wherein the organic acid is a C 1-6 alkyl or C 2-6 alkenyl substituted with 1, 2, or 3 carboxylic acid groups and substituted with 0, 1, or 2 alcohol groups.